Rhumbline Advisers Has $643,000 Stake in Enfusion, Inc. (NYSE:ENFN)

Rhumbline Advisers raised its stake in shares of Enfusion, Inc. (NYSE:ENFN) by 3.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 62,464 shares of the company’s stock after buying an additional 1,796 shares during the quarter. Rhumbline Advisers’ holdings in Enfusion were worth $643,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of ENFN. Harbor Capital Advisors Inc. raised its position in Enfusion by 12.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after buying an additional 1,315 shares during the last quarter. Versor Investments LP bought a new position in shares of Enfusion during the 3rd quarter worth approximately $501,000. Impax Asset Management Group plc raised its holdings in shares of Enfusion by 25.4% in the third quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock valued at $6,424,000 after purchasing an additional 136,948 shares during the last quarter. Royce & Associates LP lifted its position in shares of Enfusion by 35.4% in the third quarter. Royce & Associates LP now owns 99,715 shares of the company’s stock worth $946,000 after purchasing an additional 26,045 shares in the last quarter. Finally, Gladius Capital Management LP lifted its position in shares of Enfusion by 160.5% in the third quarter. Gladius Capital Management LP now owns 69,694 shares of the company’s stock worth $661,000 after purchasing an additional 42,939 shares in the last quarter. 81.05% of the stock is owned by institutional investors.

Insider Transactions at Enfusion

In other news, CFO Bradley Herring sold 4,645 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total value of $52,860.10. Following the completion of the transaction, the chief financial officer now directly owns 324,689 shares in the company, valued at approximately $3,694,960.82. This trade represents a 1.41 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Neal Pawar sold 14,560 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $11.38, for a total value of $165,692.80. Following the transaction, the chief operating officer now owns 1,217,067 shares of the company’s stock, valued at approximately $13,850,222.46. The trade was a 1.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 101,789 shares of company stock worth $1,127,449 in the last ninety days. Company insiders own 36.44% of the company’s stock.

Wall Street Analysts Forecast Growth

ENFN has been the topic of a number of analyst reports. Piper Sandler upped their price objective on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research note on Monday, December 23rd. Stifel Nicolaus boosted their target price on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. Finally, William Blair reiterated a “market perform” rating on shares of Enfusion in a research note on Monday, January 13th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Enfusion presently has an average rating of “Hold” and a consensus target price of $11.13.

Enfusion Trading Down 0.5 %

Shares of ENFN opened at $11.24 on Friday. The firm’s fifty day simple moving average is $10.98 and its two-hundred day simple moving average is $9.88. Enfusion, Inc. has a 12 month low of $7.83 and a 12 month high of $11.80. The stock has a market capitalization of $1.44 billion, a P/E ratio of 280.95, a price-to-earnings-growth ratio of 1.85 and a beta of 0.95.

Enfusion (NYSE:ENFN) last released its quarterly earnings data on Monday, March 3rd. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02). The firm had revenue of $52.94 million for the quarter, compared to the consensus estimate of $53.98 million. Enfusion had a net margin of 1.70% and a return on equity of 6.67%. As a group, research analysts predict that Enfusion, Inc. will post 0.06 EPS for the current fiscal year.

Enfusion Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.